BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Douglass CH, Pedrana A, Lazarus JV, 't Hoen EFM, Hammad R, Leite RB, Hill A, Hellard M. Pathways to ensure universal and affordable access to hepatitis C treatment. BMC Med 2018;16:175. [PMID: 30296935 DOI: 10.1186/s12916-018-1162-z] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Spearman CW, Dusheiko GM, Hellard M, Sonderup M. Hepatitis C. Lancet. 2019;394:1451-1466. [PMID: 31 DOI: 10.1016/s0140-6736(19)32320-7] [Cited by in Crossref: 108] [Cited by in F6Publishing: 56] [Article Influence: 2.3] [Reference Citation Analysis]
2 Lazarus JV, Pericàs JM, Picchio C, Cernosa J, Hoekstra M, Luhmann N, Maticic M, Read P, Robinson EM, Dillon JF. We know DAAs work, so now what? Simplifying models of care to enhance the hepatitis C cascade. J Intern Med 2019;286:503-25. [PMID: 31472002 DOI: 10.1111/joim.12972] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 11.7] [Reference Citation Analysis]
3 Kohler JC, Mackey TK. Why the COVID-19 pandemic should be a call for action to advance equitable access to medicines. BMC Med 2020;18:193. [PMID: 32586387 DOI: 10.1186/s12916-020-01661-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
4 Brunner N, Bruggmann P. Trends of the Global Hepatitis C Disease Burden: Strategies to Achieve Elimination. J Prev Med Public Health 2021;54:251-8. [PMID: 34370938 DOI: 10.3961/jpmph.21.151] [Reference Citation Analysis]
5 Piecha F, Gänßler JM, Ozga AK, Wehmeyer MH, Dietz J, Kluwe J, Laschtowitz A, von Felden J, Sterneck M, Jordan S, Pischke S, Lohse AW, Schulze Zur Wiesch J. Treatment and re-treatment results of HCV patients in the DAA era. PLoS One 2020;15:e0232773. [PMID: 32369527 DOI: 10.1371/journal.pone.0232773] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
6 Wuerth K, Magel T, Conway B. Sofosbuvir and velpatasvir in the treatment of chronic hepatitis C. Future Virology 2019;14:715-27. [DOI: 10.2217/fvl-2019-0104] [Reference Citation Analysis]
7 Lazarus JV, Roel E, Elsharkawy AM. Hepatitis C Virus Epidemiology and the Impact of Interferon-Free Hepatitis C Virus Therapy. Cold Spring Harb Perspect Med. 2020;10. [PMID: 31570385 DOI: 10.1101/cshperspect.a036913] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
8 Doyle JS, van Santen DK, Iser D, Sasadeusz J, O'Reilly M, Harney B, Traeger MW, Roney J, Cutts JC, Bowring AL, Winter R, Medland N, Fairley CK, Moore R, Tee B, Asselin J, El-Hayek C, Hoy JF, Matthews GV, Prins M, Stoové MA, Hellard ME. Micro-elimination of hepatitis C among people with HIV coinfection: declining incidence and prevalence accompanying a multi-center treatment scale-up trial. Clin Infect Dis 2020:ciaa1500. [PMID: 33010149 DOI: 10.1093/cid/ciaa1500] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Akiyama MJ, Muller A, Huang O, Lizcano J, Nyakowa M, Riback L, Ross J, Bundi H, Kulabi ES, Mwangi AM, Musyoki H, Cherutich P, Kurth A. Hepatitis C-related knowledge, attitudes and perceived risk behaviours among people who inject drugs in Kenya: A qualitative study. Glob Public Health 2021;:1-13. [PMID: 33689563 DOI: 10.1080/17441692.2021.1896763] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Schröeder SE, Pedrana A, Scott N, Wilson D, Kuschel C, Aufegger L, Atun R, Baptista-Leite R, Butsashvili M, El-Sayed M, Getahun A, Hamid S, Hammad R, 't Hoen E, Hutchinson SJ, Lazarus JV, Lesi O, Li W, Binti Mohamed R, Olafsson S, Peck R, Sohn AH, Sonderup M, Spearman CW, Swan T, Thursz M, Walker T, Hellard M, Howell J. Innovative strategies for the elimination of viral hepatitis at a national level: A country case series. Liver Int 2019;39:1818-36. [PMID: 31433902 DOI: 10.1111/liv.14222] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
11 Klein MB. Hepatitis C virus elimination: time for disruptive innovation. J Int AIDS Soc 2019;22:e25360. [PMID: 31347280 DOI: 10.1002/jia2.25360] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
12 Luna F, Luyckx VA. Why have Non-communicable Diseases been Left Behind? Asian Bioeth Rev 2020;12:5-25. [PMID: 33717328 DOI: 10.1007/s41649-020-00112-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
13 Cuypers L, Thijssen M, Shakibzadeh A, Sabahi F, Ravanshad M, Pourkarim MR. Next-generation sequencing for the clinical management of hepatitis C virus infections: does one test fits all purposes? Crit Rev Clin Lab Sci 2019;56:420-34. [PMID: 31317801 DOI: 10.1080/10408363.2019.1637394] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
14 Lim AG, Scott N, Walker JG, Hamid S, Hellard M, Vickerman P. Health and economic benefits of achieving hepatitis C virus elimination in Pakistan: A modelling study and economic analysis. PLoS Med 2021;18:e1003818. [PMID: 34665815 DOI: 10.1371/journal.pmed.1003818] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Rajasekaran A, Franco RA, Overton ET, McGuire BM, Towns GC, Locke JE, Sawinski DL, Bell EK. Updated Pathway to Micro-elimination of Hepatitis C Virus in the Hemodialysis Population. Kidney Int Rep 2021;6:1788-98. [PMID: 34307975 DOI: 10.1016/j.ekir.2021.04.015] [Reference Citation Analysis]
16 Zampirolli Dias C, Godman B, Gargano LP, Azevedo PS, Garcia MM, Souza Cazarim M, Pantuzza LLN, Ribeiro-Junior NG, Pereira AL, Borin MC, de Figueiredo Zuppo I, Iunes R, Pippo T, Hauegen RC, Vassalo C, Laba TL, Simoens S, Márquez S, Gomez C, Voncina L, Selke GW, Garattini L, Kwon HY, Gulbinovic J, Lipinska A, Pomorski M, McClure L, Fürst J, Gambogi R, Ortiz CH, Canuto Santos VC, Araújo DV, Araujo VE, Acurcio FA, Alvares-Teodoro J, Guerra-Junior AA. Integrative Review of Managed Entry Agreements: Chances and Limitations. Pharmacoeconomics 2020;38:1165-85. [PMID: 32734573 DOI: 10.1007/s40273-020-00943-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
17 Angrist M, Yang A, Kantor B, Chiba-Falek O. Good problems to have? Policy and societal implications of a disease-modifying therapy for presymptomatic late-onset Alzheimer's disease. Life Sci Soc Policy 2020;16:11. [PMID: 33043412 DOI: 10.1186/s40504-020-00106-2] [Reference Citation Analysis]
18 Heard E, Massi L, Smirnov A, Selvey LA. Prescribing direct-acting antivirals to treat hepatitis C virus in a general practice setting in Australia: 'so why not do it'? Intern Med J 2020;50:1053-8. [PMID: 31589351 DOI: 10.1111/imj.14648] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Sun J, Cheng H, Hassan MRA, Chan HK, Piedagnel JM. What China can learn from Malaysia to achieve the goal of "eliminate hepatitis C as a public health threat" by 2030 - a narrative review. Lancet Reg Health West Pac 2021;16:100261. [PMID: 34590064 DOI: 10.1016/j.lanwpc.2021.100261] [Reference Citation Analysis]
20 Karlsen TH, Sheron N, Zelber-Sagi S, Carrieri P, Dusheiko G, Bugianesi E, Pryke R, Hutchinson SJ, Sangro B, Martin NK, Cecchini M, Dirac MA, Belloni A, Serra-Burriel M, Ponsioen CY, Sheena B, Lerouge A, Devaux M, Scott N, Hellard M, Verkade HJ, Sturm E, Marchesini G, Yki-Järvinen H, Byrne CD, Targher G, Tur-Sinai A, Barrett D, Ninburg M, Reic T, Taylor A, Rhodes T, Treloar C, Petersen C, Schramm C, Flisiak R, Simonova MY, Pares A, Johnson P, Cucchetti A, Graupera I, Lionis C, Pose E, Fabrellas N, Ma AT, Mendive JM, Mazzaferro V, Rutter H, Cortez-Pinto H, Kelly D, Burton R, Lazarus JV, Ginès P, Buti M, Newsome PN, Burra P, Manns MP. The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet 2022;399:61-116. [PMID: 34863359 DOI: 10.1016/S0140-6736(21)01701-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Chan HK, Hassali MA, Mohammed NS, Azlan A, Hassan MRA. Barriers to scaling up hepatitis C treatment in Malaysia: a qualitative study with key stakeholders. BMC Public Health 2022;22:371. [PMID: 35189876 DOI: 10.1186/s12889-022-12786-w] [Reference Citation Analysis]
22 Saludes V, Antuori A, Lazarus JV, Folch C, González-Gómez S, González N, Ibáñez N, Colom J, Matas L, Casabona J, Martró E. Evaluation of the Xpert HCV VL Fingerstick point-of-care assay and dried blood spot HCV-RNA testing as simplified diagnostic strategies among people who inject drugs in Catalonia, Spain. Int J Drug Policy 2020;80:102734. [PMID: 32470849 DOI: 10.1016/j.drugpo.2020.102734] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
23 Matičič M, Lombardi A, Mondelli MU, Colombo M; ESCMID Study Group for Viral Hepatitis (ESGVH). Elimination of hepatitis C in Europe: can WHO targets be achieved? Clin Microbiol Infect 2020;26:818-23. [PMID: 31978546 DOI: 10.1016/j.cmi.2020.01.014] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
24 Chan H, Hassali MA, Md Said R, Abu Hassan MR. Treatment Coverage and Drug Expenditure in Hepatitis C Patients From 2013 to 2019: A Journey of Improving Treatment Accessibility in Malaysia Through Government-led Initiatives. Hepat Mon 2020;20. [DOI: 10.5812/hepatmon.107372] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
25 Ward Z, Campbell L, Surey J, Platts S, Glass R, Hickman M, Story A, Vickerman P. The cost-effectiveness of an HCV outreach intervention for at-risk populations in London, UK. J Antimicrob Chemother 2019;74:v5-v16. [PMID: 31782503 DOI: 10.1093/jac/dkz451] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
26 Chan H, Hassali MA, Md Said R, Omar H, Abd Mutalib NA, De Rozario FW, Abu Hassan MR. A Two-Year Outcome Evaluation of Government-Led Initiative to Upscale Hospital-based Hepatitis C Treatment Using a Standard Two-Drug Regimen in Malaysia. Hepat Mon 2021;21. [DOI: 10.5812/hepatmon.113226] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
27 Heard E, Smirnov A, Massi L, Selvey LA. Personal, provider and system level barriers and enablers for hepatitis C treatment in the era of direct-acting antivirals: Experiences of patients who inject drugs accessing treatment in general practice settings in Australia. J Subst Abuse Treat 2021;127:108460. [PMID: 34134878 DOI: 10.1016/j.jsat.2021.108460] [Reference Citation Analysis]
28 Hassan MRA, Chan H. Comment on: “Projections of the Healthcare Costs and Disease Burden due to Hepatitis C Infection Under Different Treatment Policies in Malaysia, 2018–2040”. Appl Health Econ Health Policy 2020;18:139-40. [DOI: 10.1007/s40258-019-00543-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
29 Krueger H, Robinson S, Hancock T, Birtwhistle R, Buxton JA, Henry B, Scarr J, Spinelli JJ. Priorities among effective clinical preventive services in British Columbia, Canada. BMC Health Serv Res 2022;22:564. [PMID: 35473549 DOI: 10.1186/s12913-022-07871-0] [Reference Citation Analysis]
30 Rachev B, Uyei J, Singh R, Kowal S, Johnson CE. Stakeholder point of view on prescription drug affordability - a systematic literature review and content analysis. Health Policy 2021;125:1158-65. [PMID: 34281700 DOI: 10.1016/j.healthpol.2021.06.013] [Reference Citation Analysis]
31 Amoako A, Ortiz-Paredes D, Engler K, Lebouché B, Klein MB. Patient and provider perceived barriers and facilitators to direct acting antiviral hepatitis C treatment among priority populations in high income countries: A knowledge synthesis. Int J Drug Policy 2021;:103247. [PMID: 33853727 DOI: 10.1016/j.drugpo.2021.103247] [Reference Citation Analysis]
32 Hellard M, Schroeder SE, Pedrana A, Doyle J, Aitken C. The Elimination of Hepatitis C as a Public Health Threat. Cold Spring Harb Perspect Med 2020;10:a036939. [PMID: 31712223 DOI: 10.1101/cshperspect.a036939] [Reference Citation Analysis]
33 Pourmarzi D, Hall L, Hepworth J, Smirnov A, Rahman T, Fitzgerald G. Clinical effectiveness, cost effectiveness and acceptability of community-based treatment of hepatitis C virus infection: A mixed method systematic review. J Viral Hepat 2019;26:432-53. [DOI: 10.1111/jvh.13045] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
34 Howell J, Pedrana A, Schroeder SE, Scott N, Aufegger L, Atun R, Baptista-Leite R, Hirnschall G, 't Hoen E, Hutchinson SJ, Lazarus JV, Olufunmilayo L, Peck R, Sharma M, Sohn AH, Thompson A, Thursz M, Wilson D, Hellard M. A global investment framework for the elimination of hepatitis B. J Hepatol 2021;74:535-49. [PMID: 32971137 DOI: 10.1016/j.jhep.2020.09.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
35 Martinez MA, Franco S. Discovery and Development of Antiviral Therapies for Chronic Hepatitis C Virus Infection. Adv Exp Med Biol 2021;1322:139-57. [PMID: 34258740 DOI: 10.1007/978-981-16-0267-2_6] [Reference Citation Analysis]
36 Abbas MZ. Strategic use of patent opposition safeguard to improve equitable access to innovative health technologies: A case study of CAR T-cell therapy Kymriah. Glob Public Health 2020;:1-11. [PMID: 33031009 DOI: 10.1080/17441692.2020.1825769] [Reference Citation Analysis]
37 Castro Filho EC, Piedade J, Castro R, Luz PM, Fernandes F, Grinsztejn B, Veloso VG, Pereira GH, Perazzo H. Effectiveness of direct-acting agents for chronic hepatitis C treatment in South America: A systematic review and meta-analysis. J Viral Hepat 2020;27:1396-407. [PMID: 32706518 DOI: 10.1111/jvh.13364] [Reference Citation Analysis]
38 Rhodes N, van de Pas R. Mapping buyer's clubs; what role do they play in achieving equitable access to medicines? Glob Public Health 2021;:1-12. [PMID: 34392817 DOI: 10.1080/17441692.2021.1959940] [Reference Citation Analysis]